Search Within

Gilles Andre Salles

Formats
  1. Meeting Abstract (181)
  2. Journal Article (75)
  3. Research Letter (18)
  4. Review (17)
  5. Editorial (5)
  6. Correspondence (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Section (1)
Groups
  1. Department of Medicine (304)
  2. Hematologic Malignancies, Division of (304)
  3. Center for Hematologic Malignancies (164)
  4. Lymphoma (160)
  5. Survivorship Research (116)
  6. Graduate Medical Education (107)

More Groups

People
  1. Maria Palomba (109)
  2. Andrew Zelenetz (74)
  3. Lorenzo Falchi (64)
  4. Anita Kumar (63)
  5. Gunjan Shah (62)
  6. Miguel-Angel Perales (59)

More People

Years
  1. 2025 (21)
  2. 2024 (67)
  3. 2023 (97)
  4. 2022 (69)
  5. 2021 (44)
  6. 2020 (6)
Publications
  1. Blood (126)
  2. Hematological Oncology (28)
  3. Journal of Clinical Oncology (18)
  4. Blood Advances (16)
  5. Haematologica (14)
  6. British Journal of Haematology (9)

More Publications

Publishers
  1. American Society of Hematology (143)
  2. Wiley Blackwell (30)
  3. Elsevier Inc. (20)
  4. American Society of Clinical Oncology (18)
  5. Ferrata Storti Foundation (14)
  6. Nature Publishing Group (14)

More Publishers

Results (304)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Radiotherapy as an effective bridge for relapsed/refractory secondary CNS lymphoma
    Meeting Abstract

    Cederquist, G.; Tringale, K.; Hajj, C.; Hubbeling, H.; Ma, J.; Dreyfuss, A.; Fregonese, B.; Salles, G.; Grommes, C.; Scordo, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-life experience with lenalidomide plus anti-CD20 antibodies for the treatment of patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Cassanello, G.; Rivas-Delgado, A.; Luna De Abia, A.; Corona, M.; Luttwak, E.; Okwali, M.; Isgor, I.; Galera, P.; Boardman, A. P.; Caron, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • 18F-FDG PET/CT imaging biomarkers for car-T cell therapy outcomes in large-B-cell lymphoma
    Meeting Abstract

    Leithner, D.; Flynn, J. R.; Devlin, S. M.; Mauguen, A.; Fei, T.; Zeng, S.; Imber, B. S.; Hubbeling, H.; Mayerhoefer, M.; Luttwak, E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
    Research Letter

    Qualls, D. A.; Lambert, N.; Caimi, P. F.; Merrill, M.; Pullarkat, P.; Godby, R. C.; Bond, D. A.; Wehmeyer, G. T.; Romancik, J.; Amoozgar, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Epidemiological impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) use in previously untreated diffuse large B-cell lymphoma (DLBCL) on second line (2L) treatment: An ad hoc analysis from POLARIX study
    Meeting Abstract

    Oellerich, T.; Boissard, F.; Tilly, H.; Lenz, G.; Collins, G. P.; Pinto, A.; Sehn, L. H.; Salles, G.; Roussel, M.; Simonella, L.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study
    Meeting Abstract

    Düll, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Risk profiling of patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): 3-year update of the POLARIX study
    Meeting Abstract

    Oellerich, T.; Lenz, G.; Herrera, A. F.; McCord, R.; Kimes, P.; Jardin, F.; Trnény, M.; Flowers, C. R.; Sehn, L. H.; Salles, G.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • A reproducible inflammatory biomarker signature identifies non-Hodgkin lymphoma patients at high risk of CAR-T treatment failure across different cohorts
    Meeting Abstract

    Raj, S.; Perales, M. A.; Fei, T.; Fein, J.; Tomas, A. A.; De LaPuerta, M. C.; Dahi, P.; Danylesko, I.; Epstein-Peterson, Z.; Fried, S.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX
    Journal Article

    Liao, M. Z.; Deng, R.; Gibiansky, L.; Lu, T.; Agarwal, P.; Dere, R.; Lee, C.; Hirata, J.; Herbaux, C.; Salles, G.; more...
    CTS-Clinical and Translational Science (2023)

    Fulltext@MSK | Save